---
title: Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling
subtitle: "---"
author: "**Nan-Hung Hsieh, PhD**"
date: .small[Postdoctoral Research Associate]
output: 
  xaringan::moon_reader:
    lib_dir: libs
    css: ["default", "tamu.css", "tamu-fonts.css"]
    nature:
      highlightLines: true

---

class: center, middle

```{r setup, include=FALSE}
library(sensitivity)
htmltools::tagList(rmarkdown::html_dependency_font_awesome())

```

.xxxlarge[
**Why We Need to Do  
.bolder[Computational Modeling]  
in Toxicology/Pharmacology?**
]

---

class: center, middle

.xlarge[**Reduce the use of experimental animals**]

--

.xlarge[**Enable _in vitro_ to _in vivo_ extrapolation (IVIVE)**]

--

.xlarge[**Health risk assessment**

        .  
        .  
        .  ]

???

in vitro-in vivo extrapolation ("IVIVE") of high throughput screening data (e.g., ToxCast) to real-world exposures via reverse dosimetry

---

class: middle

.xlarge[
>“The application of mathematical and computer models to predict adverse effects and to better understand the single or multiple mechanisms through which a given chemical induces harm."

>-- US Environmental Protection Agency
]

---

# What is Pharmacokinetics (PK)

--

.large[
- The fate of chemical in a living organism
- .bolder[ADME] process 

.center[

.bolder[A]bsorption - How will it get in?

.bolder[D]istribution - Which tissue organ it will go?

.bolder[M]etabolism - How is it broken down and transformation?

.bolder[E]limination - How dose it leave the body?

]
]

???
Pharmacokinetics is the application of kinetics to drug. Kinetics is that branch of knowledge which involves the change of one or more variables as a function of time. 

---

background-image: url(https://image.ibb.co/jNZi4e/drug_concentration_time.png)
background-size: 150px
background-position: 80% 98%


# What is Pharmacokinetics (PK)

.large[
- The fate of chemical in a living organism
- .bolder[ADME] process

.center[

.bolder[A]bsorption - How will it get in?

.bolder[D]istribution - Which tissue organ it will go?

.bolder[M]etabolism - How is it broken down and transformation?

.bolder[E]limination - How dose it leave the body?

]
]

.large[
- Kinetics: rates of change
- PK is focus on .bolder[TIME (t)] and .bolder[CONCENTRATION (C)]
]

???

---

# Pharmacokinetics Model

To .large[.bolder["predict"]] the exposure  concentration by constructing the **compartmental model** or non-compartmental model.

.pull-left[
<img src="http://www.mdpi.com/mca/mca-23-00027/article_deploy/html/images/mca-23-00027-g006.png" height="140px" />
]

.pull-right[
<img src="https://image.ibb.co/nJTM7z/fitting.png" height="140px" />
]

$D$: Intake dose (mass)

$C$: Concentration (mass/volumn)

$k_a$: Absorption rate (1/time)

$V_{max}$: Maximal metabolism rate

$K_m$: Concentration of chemical achieve half $V_{max}$ (mass/volumn)

$k_{el}$: elimination rate (/time)


???
It quantify the fate of drug, which is ADME
The top-right diagram is a simple example of PK model 

---

## Physiological-Based Pharmacokinetic (PBPK) Model

Mathematically transcribing .bolder[anatomical, physiological, physical, and chemical] descriptions of the phenomena involved in the complex .bolder[ADME] processes.

.shrink[
![](http://pharmguse.net/pkdm/pbpm.jpg)
]

---

# Population PBPK

.large[

- Limited data (sparse data) for each individual within the population 

- Characterize PK parameters for populations

- Cross-species  comparisons of metabolism or absorption

- Evaluating population variability 

- Evaluating uncertainty

]

---


class: center

# Modeling Workflow

.left[**Model calibration** (Bayesian hierarchical modeling)]

Prior knowledge (expertise or historical data)  
<img src="https://image.ibb.co/fATCee/Screen_Shot_2018_09_03_at_10_19_27_AM.png" height="80px" />

<i class="fa fa-arrow-down"></i>

.bolder[Markov Chain Monte Carlo algorithm]

<i class="fa fa-arrow-down"></i>

Posterior knowledge  
<img src="https://image.ibb.co/fQuKQK/Screen_Shot_2018_09_03_at_3_32_28_PM.png" height="80px" />

.left[**Model validation**]

Compare the result of **in-silico simulation** and **in-vivo observation**

---

# Tools

## [GNU MCSim](http://www.gnu.org/software/mcsim/)

.large[
- Design and run statistical or simulation models (e.g., differential equations)

- Do parametric simulations (e.g., sensitivity analysis)

- Perform Monte Carlo (stochastic) simulations

.highlight[
- Do Bayesian inference for hierarchical models through .bolder[Markov Chain Monte Carlo] simulations
]
]


</br>

[*] It can run under Unix/Linux, Windows, Mac OS
---

# Challenge

.large[Currently, the **Bayesian Markov chain Monte Carlo algorithm** is a effective way to do PBPK model calibration. ]

.xlarge[.bolder[BUT]]

--

.large[
This method often have challenges to reach **"convergence"** with acceptable computational times .bolder[(More parameters, More time!)]
]

.right[![](https://slides.yihui.name/gif/questions.gif)]

---

class: middle, center

## Sometimes, the result is bad ...

![](https://slides.yihui.name/gif/dump-computer.gif)

---

class: center, middle

.xxxlarge[**Our Problem Is ...**]

--

</br>

.xxxlarge[**How to Improve the .bolder[Computational Efficiency]**]

---

# Project

Funder: **Food and Drug Administration (FDA)**

Project Start: **Sep-2016**

Name: **Enhancing the reliability, efficiency, and usability of Bayesian population PBPK modeling**

--

  - Specific Aim 1: Develop, implement, and evaluate methodologies for parallelizing time-intensive calculations and enhancing a simulated tempering-based MCMC algorithm for Bayesian parameter estimation  
  (.bolder[Revise algorithm in model calibration])

--
  
  - Specific Aim 2: Create, implement, and evaluate a robust Global Sensitivity Analysis algorithm to reduce PBPK model parameter dimensionality  
  (.bolder[Parameter fixing])

--

  - Specific Aim 3: Design, build, and test a user-friendly, open source computational platform for implementing an integrated approach for population PBPK modeling  
  (.bolder[User friendly interface])

---

# Proposed Solution - Parameter Fixing 

.large[We usually fix the **"possible"** non-influential model parameters through **"expert judgment"**.]

.xlarge[.bolder[BUT]]

--

.large[This approach might cause **"bias"** in parameter estimates and model predictions.]

.pull-left[
.center[![](http://reliawiki.org/images/3/35/Doe34.png)]
]

.pull-right[
<img src="https://njtierney.updog.co/gifs/narnia-dart-throw.gif" height="240px" />
]

---

# Propose solution for parameter fixing 

## Sensitivity Analysis

</br>

.large[
>Sensitivity analysis is "the study of how the uncertainty in the output of a model (numerical or otherwise) can be apportioned to different sources of uncertainty in the model input." 

> -- [Andrea Saltelli]((http://www.andreasaltelli.eu/file/repository/intro_v2b)

]

.footnote[[Saltelli A., 2002, Sensitivity Analysis for Importnace Assessment, Risk Analysis, 22 (3) 1-12.](http://www.andreasaltelli.eu/file/repository/intro_v2b)]

---

# When we need SA?

--

.xlarge[.bolder[Parameter Priorization]]

</br>

</br>

.xlarge[.bolder[Parameter Fixing]]

</br>

</br>

.xlarge[.bolder[Parameter Mapping]]

---

# Why we need SA?

.xlarge[.bolder[Parameter Priorization]]

- Identifying the most important factors

- Reduce the uncertainty in the model response if it is too large (ie not acceptable)

.xlarge[.bolder[Parameter Fixing]]

</br>

</br>

.xlarge[.bolder[Parameter Mapping]]


---

# Why we need SA?

.xlarge[.bolder[Parameter Priorization]]

- Identifying the most important factors

- Reduce the uncertainty in the model response if it is too large (ie not acceptable)

.xlarge[.bolder[Parameter Fixing]]

- Identifying the least important factors

- Simplify the model if it has too many factors

.xlarge[.bolder[Parameter Mapping]]

--

- Identify critical regions of the inputs that are responsible for extreme value of the model response

---


# Classification of SA Methods


.pull-left[

**Local** (One-at-a-time)

<img src="http://evelynegroen.github.io/assets/images/fig11local.jpg" height="240px" />

**"Local"** SA focus on sensitivity at a particular set of input parameters, usually using gradients or partial derivatives

]

--

.pull-right[

**Global** (All-at-a-time)

<img src="http://evelynegroen.github.io/assets/images/fig2global.jpg" height="240px" />

**"Global"** SA calculates the contribution from the variety of all model parameters, including .bolder[Single parameter effects] and .bolder[Multiple parameter interactions]

]

--

.large[.center[**"Global" sensitivity analysis is good at** .bolder[parameter fixing]]]

---

class: center

# Sensitivity index

.xlarge[First order] $(S_i)$

</br> 
</br> 

.xlarge[Interaction] $(S_{ij})$

</br> 

.xlarge[Total order] $(S_{T})$

</br> 
</br> 

---

class: center

# Sensitivity index

.xlarge[First order] $(S_i)$

The output variance contributed by the specific parameter $x_i$,  
also known as **main effect**

.xlarge[Interaction] $(S_{ij})$

</br> 

.xlarge[Total order] $(S_{T})$

</br> 
</br> 

---

class: center

# Sensitivity index

.xlarge[First order] $(S_i)$

The output variance contributed by the specific parameter $x_i$,  
also known as **main effect**

.xlarge[Interaction] $(S_{ij})$

The output variance contributed by any pair of input parameter

.xlarge[Total order] $(S_{T})$

--

The output variance contributed by the specific parameter and interaction,  
also known as **total effect**

--

<hr/>

.left[
.bolder[“Local”] SA usually only addresses first order effects

.bolder[“Global”] SA can address total effect that include main effect and interction
]

---

# Challenges in GSA-PBPK modeling

</br>

.xxlarge[
Too many algorithms have been develped, but we don't have knowlege to identify which one is the best
]

</br>

.xxlarge[
No suitable reference in parameter fixing for PBPK model
]



---

class: middle

# Hypothesis

.large[
.bolder[Global Sensitivity Analysis] can provide a systematic method to ascertain which PBPK model parameters have **negligible influence** on model outputs and can be fixed to improve computational speed in Bayesian parameter estimation with **minimal bias**.
]

--

**Four Questions:**

.highlight[
.large[**What**] is the relative computational efficiency of convergence of various GSA algorithms?
]

--

.highlight[
.large[**Do**] different algorithms give consistent results as to direct and indirect parameter sensitivities?
]

--

.highlight[
.large[**Can**] we identify non-influential parameters that can be fixed in a Bayesian PBPK calibration while acheving similar degrees of accuracy and precision?
]

--

.highlight[
.large[**Does**] fixing parameters using "expert judgment" lead to unintentional imprecision or bias?
]

---

# Materials - Chemical

.center[
<img src="https://image.ibb.co/e7eccz/JjqgWwg.gif" height="200px" />
]

.bolder[Acetaminophen] (APAP) is a widely used over the 
counter (OTC) pain reliver and fever reducer.

The therapeutic index (ratio of toxic to therapeutic doses) is 
unusually small for an OTC medication.

Phase I (.bolder[APAP to NAPQI]) is Toxicity pathway at high dose.

Phase II (.bolder[APAP to APAP-G & APAP to APAP-S]) Major pathways at therapeutic dose.

--

.center[
.highlight[
A typical pharmacological agent with large amounts of 
both human and animal data.  
Well-constructed and studied PBPK model.
]
]


---

background-image: url(https://image.ibb.co/b9F8Ze/uSCphVE.gif)
background-size: 500px
background-position: 50% 80%

# Materials - PBPK Model 

The simulation of the disposition of .bolder[acetaminophen (APAP)] and two of its key metabolites, .bolder[APAP-glucuronide (APAP-G)] and .bolder[APAP-sulfate (APAP-S)], in plasma, urine, and several pharmacologically and toxicologically relevant tissues.

.footnote[[Zurlinden, T.J. & Reisfeld, B. Eur J Drug Metab Pharmacokinet (2016) 41: 267. ](https://link.springer.com/article/10.1007%2Fs13318-015-0253-x)]

???

---

# Parameters calibrated in previous study

.large[

.large[.bolder[2]] Acetaminophen absorption (Time constant)

.large[.bolder[2]] Phase I metabolism: Cytochrome P450 (M-M constant)

.large[.bolder[4]] Phase II metabolism: sulfation (M-M constant)

.large[.bolder[4]] Phase II metabolism: glucuronidation (M-M constant)

.large[.bolder[4]] Active hepatic transporters (M-M constant)

.large[.bolder[2]] Cofactor synthesis (rate constant)

.large[.bolder[3]] Clearance (rate constant)

]

---

background-image: url(https://image.ibb.co/b9F8Ze/uSCphVE.gif)
background-size: 300px
background-position: 2% 98%

#Absorption

.left-column[

]

.right-column[

Use Oral dose $(D_{oral})$ and bioavaliability $(F_A)$ and absorption parameters, we can estimate the amount of APAP absorbed into the blood stream as,

$$\frac{dA_{abs}}{dt}=\frac{F_A\cdot D_{oral}\cdot[exp(\frac{-t}{T_G})-exp(\frac{-t}{T_P})]}{T_G-T_P}$$

.highlight[
$T_g$ : Gastric emptying time constant

$T_p$ : Intestinal permeability time constant
]

]

---

background-image: url(https://image.ibb.co/e7eccz/JjqgWwg.gif)
background-size: 280px
background-position: 95% 5%

# Metabolism

.left-column[

### Phase I

]

.right-column[

Rate of phase I metabolism $(v_{cyp})$ can be estimated by concnetration of APAP in liver $(C^{APAP}_{liver})$ and 2 M-M parameters for APAP-G and APAP-S as, 


$$v_{cyp} = \frac{V_{M-cyp}\cdot C^{APAP}_{liver}}{K^{{APAP}}_{M-cyp}+C^{APAP}_{liver}}$$

</br>

.highlight[
$K^{{APAP}}_{M-cyp}$ : M-M constant $KM$ for Cytochrome P450

$V_{M-cyp}$ : Maximum conversion rate $V_{max}$ for Cytochrome P450 
]

]

---

background-image: url(https://image.ibb.co/e7eccz/JjqgWwg.gif)
background-size: 280px
background-position: 95% 5%

# Metabolism

.left-column[

### Phase I
### Phase II
]

.right-column[

The APAP conversion rate $(v_{conjugate})$ can be estimated by concnetration of APAP and fraction of cofactor in the liver $(\phi^{cf}_{liver})$ with 4 Michaelis-Menten parameters for APAP-G and APAP-S as,

$$v_{conjugate} = \frac{V_{M-enz}\cdot C^{APAP}_{liver}\cdot \phi^{cf}_{liver}}{(K^{APAP}_{M-enz}+C^{APAP}_{liver}+\frac{(C^{APAP}_{liver})^2}{K_{I-enz}})(K^{cf}_{M-enz}+\phi^{cf}_{liver})}$$

</br>

.highlight[
$V_{M-enz}$ : Enzyme-specific maximum rate of conversion

$K^{APAP}_{M-enz}$ : M-M constant for APAP

$K^{APAP}_{I-enz}$ : Inhibition constant

$K^{cf}_{M-enz}$ : Michaelis-Menten constant for cofactor
]
]

---

background-image: url(https://image.ibb.co/e7eccz/JjqgWwg.gif)
background-size: 280px
background-position: 95% 5%

# Cofactor synthesis

.left-column[

]

.right-column[
The fraction of cofactor in the liver $(A^{cf}_{liver})$ can be estimated by APAP conversion rate and a rate parameter as,

$$\frac{d\phi^{cf}_{liver}}{dt}=-v_{conjugate}+k_{syn-cf}(1-\phi^{cf}_{liver})$$

</br>

.highlight[
$k_{syn-cf}$ : rate of synthesis of the cofactor
]

]

---

background-image: url(https://image.ibb.co/b9F8Ze/uSCphVE.gif)
background-size: 300px
background-position: 2% 98%

# Active hepatic transporters

.left-column[

]

.right-column[
Rate of hepatic transport $(v^{conj}_{mem})$ can be estimated by 2 M-M parameters for APAP-G and APAP-S as, 


$$v^{conj}_{mem} = \frac{V^{conj}_{M-mem}\cdot C^{conj}_{hep}}{K^{{conj}}_{M-mem}+C^{conj}_{hep}}$$

.highlight[
$V^{conj}_{M-mem}$ : Maximum transport rate

$K^{{conj}}_{M-mem}$ : Concentration of chemical achieve half Vmax
]
]

---

background-image: url(https://image.ibb.co/b9F8Ze/uSCphVE.gif)
background-size: 300px
background-position: 2% 98%

# Clearance

.left-column[

]

.right-column[
The clearance rate can be used to estimate the amount of kidney elimination $(A^j_{KE})$

$$\frac{dA^j_{KE}}{dt}=k^j_{R0}\cdot BW \cdot C^j_A$$

</br>

.highlight[
$k^j_{R0}$ : rate of renal clearance of the chemical $j$ (represents APAP, APAP-G, and APAP-S)
]
]

---

# Parameters fixed in previous study

$$\frac{dA^T_{j}}{dt}=V_T\frac{dC^j_T}{dt}=Q_T(C^j_A-\frac{C^j_T}{P_{T:blood}})$$

</br>

.pull-left[

.large[**Physiological parameters**]

1 cardiac output

6 blood flow rate $(Q)$

8 tissue volume $(V)$

]

.pull-right[

.large[**Physicochemical parameters**]

22 partition coefficient for APAP, APAP-G, and APAP-S $(P)$

]

---

# Materials

### Experiment Data: 

Eight studies (n = 71) with single oral dose and three different given doses.

```{r, echo=F, eval=T}
Study <- c(1:8)
Dose <- c("325 mg", "1000 mg", "1000 mg", "1000 mg", "20 mg/kg", "20 mg/kg", "20 mg/kg", "20 mg/kg")
Subject <- c("8","6","5","12","8","6","11","9")
df <- data.frame(Study, Dose, Subject)
names(df) <- c("Study", "Dose", "No. of Subject")
knitr::kable(df, format = 'html', align=c("l","c","c"))
```

---

# Materials

### Experiment Data: 

Eight studies (n = 71) with single oral dose and three different given doses.

.center[
<img src="https://image.ibb.co/mfUD0K/wuYl7Bk.png" height="420px" />
]

---

# Materials

### Sensitivity Analysis: 

**Local:** 

- Morris screening

**Global:**  

- Extended Fourier Amplitude Sensitivity Testing (EFAST)

- Jansen's algorithm 

- Owen's algorithm

---

# Morris screening

- Perform parameter sampling in Latin Hypercube following One-Step-At-A-Time

- Can compute the importance $(\mu^*)$ and interaction $(\sigma)$ of the effects

.pull-left[
![](https://www.researchgate.net/profile/Valentine_Lafond/publication/280727281/figure/fig2/AS:391534521405440@1470360512078/Figure-C-2-Illustration-of-Morris-screening-method-of-factorial-space-This-figure.png)
]

.pull-right[
```{r, echo=F, warning=FALSE, eval=T, fig.width = 4, fig.height = 3, dpi = 180, out.width = "600px"}
set.seed(1111)
x <- morris(model = ishigami.fun, factors = c("Factor A", "Factor B","Factor C"), r = 30,
            binf = -pi, bsup = pi,
            design = list(type = "oat", levels = 5, grid.jump = 3))
par(mar=c(4,4,1,1))
plot(x, xlim = c(5,20), ylim = c(5,10))
```
]

--

.highlight[
**1. It is semi-quantitative – the factors are ranked on an interval scale**  
**2. It is numerically efficient**  
**3. Not very good for factor fixing**
]

---

# Variance-based sensitivity analysis

EFAST defines a .bolder[search curve] in the input space

$$x_i=\frac{1}{2}+\frac{1}{\pi}\arcsin(\sin(\omega\cdot s+\phi_i))$$

.pull-left[
.center[
![](https://upload.wikimedia.org/wikipedia/commons/6/64/Search_curve_1.gif)
]
]

.pull-right[
.center[
![](https://upload.wikimedia.org/wikipedia/commons/2/29/Search_curve_3.gif)
]
]

---

# Variance-based sensitivity analysis

Jansen generates .bolder[TWO] independent random sample with $N$ points in d dimensions.

Owen combines .bolder[THREE] independent random sampling parameter matrix

.pull-left[

![](https://image.ibb.co/kvyPFK/mc_animation.gif)

]

.pull-right[
```{r, echo=F, warning=FALSE, eval=T, fig.width = 6, fig.height = 5, dpi = 180}
set.seed(1234)
x <- fast99(model = ishigami.fun, factors = c("Factor A", "Factor B","Factor C"), n = 1000,
            q = "qunif", q.arg = list(min = -pi, max = pi))
par(mar=c(4,4,4,1))
plot(x)
```
]

--

.highlight[
1. **Full quantitative** 
2. **The computational cost is more expensive**
3. **Good for factor fixing**
]

---

### The basic step to performing UA and SA

1. Define the variable of interest $(y)$

    - **APAP, APAP-G, APAP-S in serum**

2. Identify model parameters $(x_i)$ which should be consider in GSA

    - **Selected parameters in previous study & all model parameters**

3. Characterise the uncertainty for each selected input factor

    - **Prior knowledge for each parameter in PBPK model**
    
    - **Possible model simulation**

4. Generate a sample of a given size from the previously defined probability distribution.

    - **Sample number from $2^{10}$ to $2^{13}$**

5. Estimate the sensitivity measures

6. Set **cut-off** for parameter fixing

---

class: center

# Sensitivity Analysis (SA) Workflow


.large[Reproduce result from original paper (21 parameters)] 


<i class="fa fa-arrow-down"></i>


.large[Full model calibration (58 parameters)] 


<i class="fa fa-arrow-down"></i>

--

.highlight[
.large[Sensitivity Analysis using different sensitivity analysis algorithms] 

**Compare the .bolder[time-cost, stability] under the same sample number (Q1)**  
**Compare the .bolder[consistency] across different algorithms (Q2)**
]


--

<i class="fa fa-arrow-down"></i>

.highlight[
.large[Model calibration by SA-judged influential parameters]   

**Compare the .bolder[model performance] in accuracy and precision (Q3)**  
**Exam the  .bolder[bias] for expert and SA-judged parameters (Q4)**
]

---

### Q1: What is the relative computational efficiency of various GSA algorithms?

--

.center[
<img src="https://image.ibb.co/mYWr5K/fig1.jpg" height="420px" />  
]

Time-spend in SA (min): Morris (2.4) < **EFAST (19.8)** $\approx$ Jansen (19.8) < Owen (59.4)

Variation of SA index: Morris (2.3%) < **EFAST (5.3%)** < Jansen (8.0%) <  Owen (15.9%)

---

### Q1: What is the relative computational efficiency of various GSA algorithms?

.center[
<img src="https://image.ibb.co/mYWr5K/fig1.jpg" height="420px" />  
]

.center[
.highlight[
**Ans 1: The Morris method provided the most efficient computational performance and convergence result, followed by eFAST**
]
]

---

### Q2: Do different algorithms give consistent results as to direct parameter sensitivities?

---

.left-column[
Original parameters
### Local SA
]

.right-column[

![](https://image.ibb.co/hnStpp/figS2.jpg)

]

---

.left-column[
Original parameters
### Local SA
### Global SA 
]

.right-column[
<img src="https://image.ibb.co/jXozUp/figS4.jpg" height="600px" />  
]

---

.left-column[
Full parameters
### Local SA
]

.right-column[
<img src="https://image.ibb.co/fsCbQU/figS5.jpg" height="600px" />  
]

---

.left-column[
Full parameters
### Local SA
### Global SA (eFAST)
]

.right-column[
<img src="https://image.ibb.co/jTM35U/figS6.jpg" height="600px" />  
]

---

### Q2: Do different algorithms give consistent results as to direct parameter sensitivities? 

.pull-left[
![](https://image.ibb.co/jKtsnz/fig2_1.jpg)
]

.pull-right[
![](https://image.ibb.co/mt11fK/fig2_2.jpg)
]

.center[
.xlarge[
.bolder[EFAST] $\approx$ Jansen $\approx$  Owen > Morris
]
]


--

.center[
.highlight[
**Ans 2: Local and global method give inconsistent results as to direct and indirect parameter sensitivities.**
]]

---

### Q3: Can we identify non-influential parameters that can be fixed in a Bayesian PBPK model calibration while achieving similar degrees of accuracy and precision?

--

.center[
<img src="https://www.frontiersin.org/files/Articles/363813/fphar-09-00588-HTML/image_m/fphar-09-00588-g003.jpg" height="500px" />  
]

.footnote[OIP: original influential parameters; OMP: original model parameters; FIP: full infliential parameter; FMP: full model parameters]

---

### The non-influential original parameters 

.bolder[1] Absorption parameters - $T_p$

.bolder[2] Phase I metabolism parameters - $K^{{APAP}}_{M-cyp}$ and $V_{M-cyp}$

.bolder[2] Inhibition constants - $K^{APAP}_{I-enz}$ 

.bolder[2] M-M constants for cofactor - $K^{cf}_{M-enz}$

### The influential additional parameters 

.bolder[1] physiological parameter - Cardiac output $(QCC)$

.bolder[1] chemical-specific transport parameter - Blood:plasma ratio of APAP $(BP_{APAP})$

.bolder[4] partition coefficients
  - Fat:blood APAP
  - Liver:blood APAP
  - Muscle:blood APAP
  - slowly perfused tissues:blood APAP [bone, heart, skin]

---

### Q3: Can we identify non-influential parameters that can be fixed in a Bayesian PBPK model calibration while achieving similar degrees of accuracy and precision?

.center[
<img src="https://image.ibb.co/g6EU4p/fig3.png" height="500px" />  
]

.footnote[OIP: original influential parameters; OMP: original model parameters; FIP: full infliential parameter; FMP: full model parameters]

---

### Q3: Can we identify non-influential parameters that can be fixed in a Bayesian PBPK model calibration while achieving similar degrees of accuracy and precision?

.center[
![](https://image.ibb.co/gUu1s9/fig5.jpg)
]

---


### Q3: Can we identify non-influential parameters that can be fixed in a Bayesian PBPK model calibration while achieving similar degrees of accuracy and precision?

- Summary of the time-cost for 
    - All model parameters (this study, 58), 
    - GSA-judged parameters (this study, 20),
    - Expert-judged parameters ([Zurlinden and Reisfeld, 2016](https://link.springer.com/article/10.1007%2Fs13318-015-0253-x), 21)

```{r, echo=F, eval=T}
x <- c("All model parameters", "GSA-judged parameters", "Expert-judged parameters")
y <- c("104.6 (0.96)", "42.1 (0.29)", "40.8 (0.18)")
df <- data.frame(x,y)
names(df) <- c("Parameter group","Time-cost in calibration (hr)")
knitr::kable(df, format = 'html', align=c("l","c"))
```

- All time-cost value are shown with mean and standard deviation (n = 10).

--

<br/>

.center[
.highlight[
**Ans 3: Restricting the MCMC simulations to the influential parameters with cut-off point at 0.01 can substantially reduce computational burden while showing little change in model performance.** 

]]


---

### Q4: Does fixing parameters using "expert judgment" lead to unintentional imprecision or bias?

--

.center[
<img src="https://www.frontiersin.org/files/Articles/363813/fphar-09-00588-HTML/image_m/fphar-09-00588-g006.jpg" height="400px" />  
]

.center[
.highlight[
**Ans 4: GSA was more effective than “expert judgment” at identifying parameters that are influential, and led to a better fit between predictions and data even though almost the same number of parameters were used.**
]]

---

# Take Home Message

- .bolder[Uncertainty and (global) sensitivity analysis] is an essential tool to reduce the dimensionality and improve the computational efficiency in model calibration.

--

- Use the .bolder[EFAST] estimator for parameter sensitivity, making sure to check convergence.

--

- Distinguish “influential” and “non-influential” parameters with .bolder[cut-off] from sensitivity index and check .bolder[accuracy] and .bolder[precision] to evulate model performance. 

--

.large[
For more details, read this ... <i class="fa fa-smile-o"></i> 
]

Hsieh N-H, Reisfeld B, Bois FY and Chiu WA (2018) Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling. *Front. Pharmacol.* 9:588. doi: 10.3389/fphar.2018.00588   
[link](https://www.frontiersin.org/articles/10.3389/fphar.2018.00588/full)  

.right[![](https://www.frontiersin.org/areas/journals/images/about-open-access.png)]


---

# What we might ignore in our study?

--

### How to applied this GSA workflow to other cases?

</br>

### Which external factors that might chenage GSA result?

- Parameter distributions?

- Different given doses? 

</br>

### How to determine the robust cut-off?

---

# Following Work

Reproducible research
- Software development 

![](https://image.ibb.co/kWrZ9p/Screen_Shot_2018_09_10_at_2_37_38_PM.png)

---

class: inverse, center, middle

## Acknowledgements

**Supervisor**  
.large[Weihsueh A. Chiu @TAMU]


**Principal investigator**  
.large[Brad Reisfeld @CSU] 


**Software & tecnical support**  
.large[Frederic Y. Bois @INERIS]


**PBPK model**  
.large[Todd Zurlinden @USEPA]


<br />

### Fouder

<img src="https://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm519147.png" height="80px" /> 

---

# Reference

**Model calibration technique**

Bois, F. Y. (2009). GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models. Bioinformatics 25, 1453–1454. doi: 10.1093/bioinformatics/btp162  
[link](https://doi.org/10.1093/bioinformatics/btp162)

**Idea of global SA-PBPK**

McNally, K., Cotton, R., and Loizou, G. D. (2011). A workflow for global sensitivity analysis of PBPK models. Front. Pharmacol. 2:31. doi: 10.3389/fphar.2011.00031   
[link](https://doi.org/10.3389/fphar.2011.00031)

**APAP-PBPK model details**

Zurlinden, T. J., and Reisfeld, B. (2016). Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach. Eur. J. Drug Metab. Pharmacokinet. 41, 267–280. doi: 10.1007/s13318-015-0253-x   
[link](https://doi.org/10.1007/s13318-015-0253-x)

---

class: inverse, middle, center

# Thanks!

Slides at: [bit.ly/180924_seminar]()

???

ENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDEND
